Screening and treatment of endocrine hypertension focusing on adrenal gland disorders: a narrative review

키워드

참고문헌 (76)

1. ". Seoul: Korean Society of Hypertension" (2022)[URL]
2. Young Jr WF, "Screening for endocrine hypertension : an endocrine society scientific statement", Endocr Rev, 38, pp.103~122 (2017)
3. Kotchen TA, "Harrison’s principles of internal medicine" (2022), McGraw-Hill Education
4. Rimoldi SF, "Secondary arterial hypertension: when, who, and how to screen?", Eur Heart J, 35, pp.1245~1254 (2014)
5. Young WF Jr, "Diagnosis and treatment of primary aldosteronism : practical clinical perspectives", J Intern Med, 285, pp.126~148 (2019)
6. Monticone S, "Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice", J Am Coll Cardiol, 69, pp.1811~1820 (2017)
7. Mulatero P, "Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents", J Clin Endocrinol Metab, 89, pp.1045~1050 (2004)
8. Mulatero P, "Guidelines for primary aldosteronism : uptake by primary care physicians in Europe", J Hypertens, 34, pp.2253~2257 (2016)
9. Choy KW, "Primary aldosteronism", BMJ, 377, pp.e065250~ (2022)
10. Vaidya A, "The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment", Endocr Rev, 39, pp.1057~1088 (2018)
11. Monticone S, "Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension : a systematic review and meta-analysis", Lancet Diabetes Endocrinol, 6, pp.41~50 (2018)
12. Burrello J, "Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit", Hypertension, 75, pp.1025~1033 (2020)
13. Ha J, "2023 Korean Endocrine Society consensus guidelines for the diagnosis and management of primary aldosteronism", Endocrinol Metab(Seoul), 38, pp.597~618 (2023)
14. Mulatero P, "Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension", J Hypertens, 38, pp.1919~1928 (2020)
15. Funder JW, "The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 101, pp.1889~1916 (2016)
16. Whelton PK, "Harmonization of the American College of Cardiology", American Heart Association and European Society of Cardiology, Hypertension Guidelines, pp.Eur Heart J, 2022[DOI]
17. Kim HL, "The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension", Clin Hypertens, 29, pp.11~ (2023)
18. Dudenbostel T, "Resistant hypertension, obstructive sleep apnoea and aldosterone", J Hum Hypertens, 26, pp.281~287 (2012)
19. Milliez P, "Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism", J Am Coll Cardiol, 45, pp.1243~1248 (2005)
20. Seccia TM, "Atrial fibrillation as presenting sign of primary aldosteronism : results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive(PAPPHY)Study", J Hypertens, 38, pp.332~339 (2020)
21. Halimi JM, "Albuminuria in untreated patients with primary aldosteronism or essential hypertension", J Hypertens, 13(12 Pt 2), pp.1801~1802 (1995)
22. Notsu M, "Primary aldosteronism as a risk factor for vertebral fracture", J Clin Endocrinol Metab, 102, pp.1237~1243 (2017)
23. Monticone S, "Renal damage in primary aldosteronism : a systematic review and meta-analysis", J Hypertens, 38, pp.3~12 (2020)
24. Faconti L, "Diagnosis and management of primary hyperaldosteronism in patients with hypertension : a practical approach endorsed by the British and Irish Hypertension Society", J Hum Hypertens, 38, pp.8~18 (2024)
25. Stowasser M, "Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism", J Clin Endocrinol Metab, 103, pp.4113~4124 (2018)
26. Kwon SY, "Aldosterone immunoassay-specific cutoff value for seated saline suppression test for diagnosing primary aldosteronism", Endocrinol Metab(Seoul), 37, pp.938~942 (2022)
27. Thuzar M, "Diagnosis of primary aldosteronism by seated saline suppression test-variability between immunoassay and HPLC-MS", MS, 2020, pp.105, e477~e483
28. Luther JM, "Unilaterally successful adrenal vein sampling : use or repeat", Hypertension, 80, pp.2014~2016 (2023)
29. Mulatero P, "Prevalence and characteristics of familial hyperaldosteronism : the PATOGEN study(Primary Aldosteronism in TOrino-GENetic forms)", Hypertension, 58, pp.797~803 (2011)
30. Tetti M, "Unilateral primary aldosteronism : long-term disease recurrence after adrenalectomy", Hypertension, 81, pp.936~945 (2024)
31. Harris DA, "Review of surgical management of aldosterone secreting tumours of the adrenal cortex", Eur J Surg Oncol, 29, pp.467~474 (2003)
32. Rossi GP, "Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism", Hypertension, 62, pp.62~69 (2013)
33. Fourkiotis V, "Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism", Eur J Endocrinol, 168, pp.75~81 (2012)
34. Williams TA, "Outcomes after adrenalectomy for unilateral primary aldosteronism : an international consensus on outcome measures and analysis of remission rates in an international cohort", Lancet Diabetes Endocrinol, 5, pp.689~699 (2017)
35. Ghose RP, "Medical management of aldosterone-producing adenomas", Ann Intern Med, 131, pp.105~108 (1999)
36. Cohen JB, "Primary aldosteronism and the role of mineralocorticoid receptor antagonists for the heart and kidneys", Annu Rev Med, 74, pp.217~230 (2023)
37. Sehgal R, "Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver", Eur J Gastroenterol Hepatol, 32, pp.535~539 (2020)
38. Pitt B, "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators", N Engl J Med, 341, pp.709~717 (1999)
39. de Gasparo M, "Antialdosterones : incidence and prevention of sexual side effects", J Steroid Biochem, 32(1B), pp.223~227 (1989)
40. Kolkhof P, "Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury", J Cardiovasc Pharmacol, 64, pp.69~78 (2014)
41. Dojki FK, "Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease", Curr Opin Nephrol Hypertens, 26, pp.368~374 (2017)
42. "Efficacy and safety of finerenone in patients with primary aldosteronism" (2024)[URL]
43. "Finerenone for Patients With Primary Aldosteronism (FAIRY)" (2024)[URL]
44. Carey RM, "Resistant hypertension : detection, evaluation, and management : a scientific statement from the American Heart Association", Hypertension, 72, pp.e53~e90 (2018)
45. Kantorovich V, "Pheochromocytoma and paraganglioma", Prog Brain Res, 182, pp.343~373 (2010)
46. Lenders JW, "Pheochromocytoma and paraganglioma : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 99, pp.1915~1942 (2014)
47. Eisenhofer G, "Screening for pheochromocytomas and paragangliomas", Curr Hypertens Rep, 14, pp.130~137 (2012)
48. Lenders JW, "Phaeochromocytoma", Lancet, 366, pp.665~675 (2005)
49. Canu L, "Pheochromocytomas and paragangliomas as causes of endocrine hypertension", Front Endocrinol(Lausanne), 10, pp.333~ (2019)
50. Melson E, "Myocardial Infarction with non-obstructed coronaries : atypical presentation of pheochromocytoma", Endocrinol Diabetes Metab Case Rep, 2019, pp.EDM190089~ (2019)
51. Lee YY, "Interleukin-6-producing paraganglioma as a rare cause of systemic inflammatory response syndrome : a case report", J Yeungnam Med Sci, 40, pp.435~441 (2023)
52. Gruber LM, "Pheochromocytoma characteristics and behavior differ depending on method of discovery", J Clin Endocrinol Metab, 104, pp.1386~1393 (2019)
53. "Clinical presentation and diagnosis of pheochromocytoma" (2024)[URL]
54. Eisenhofer G, "Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors", J Clin Endocrinol Metab, 83, pp.2175~2185 (1998)
55. Peaston RT, "Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma", Clin Chim Acta, 411, pp.546~552 (2010)
56. Mullins F, "Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal", Clin Chem Lab Med, 50, pp.105~110 (2011)
57. Neary NM, "Drugs and pheochromocytoma : don’t be fooled by every elevated metanephrine", N Engl J Med, 364, pp.2268~2270 (2011)
58. Leow MK, "Catecholamine and metanephrine excess in intracerebral haemorrhage : revisiting an obscure yet common"pseudophaeochromocytoma"", J Clin Pathol, 60, pp.583~584 (2007)
59. Grouzmann E, "Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma", Eur J Endocrinol, 162, pp.951~960 (2010)
60. Sawka AM, "A comparison of biochemical tests for pheochromocytoma : measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines", J Clin Endocrinol Metab, 88, pp.553~558 (2003)
61. Bravo EL, "Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma", Endocr Rev, 15, pp.356~368 (1994)
62. Canu L, "CT Characteristics of pheochromocytoma : relevance for the evaluation of adrenal incidentaloma", J Clin Endocrinol Metab, 104, pp.312~318 (2019)
63. Ku EJ, "Diagnosis for pheochromocytoma and paraganglioma: a joint position statement of the Korean Pheochromocytoma and Paraganglioma Task Force", Endocrinol Metab(Seoul), 36, pp.322~338 (2021)
64. Neumann HP, "Pheochromocytoma and paraganglioma", N Engl J Med, 381, pp.552~565 (2019)
65. Muth A, "Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma", J Intern Med, 285, pp.187~204 (2019)
66. Fang F, "Preoperative management of pheochromocytoma and paraganglioma", Front Endocrinol(Lausanne), 11, pp.586795~ (2020)
67. Lenders JW, "Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension", J Hypertens, 38, pp.1443~1456 (2020)
68. Sibal L, "Phaeochromocytomas presenting as acute crises after beta blockade therapy", Clin Endocrinol(Oxf), 65, pp.186~190 (2006)
69. Wang L, "Comparison of clinical efficacy and safety between robotic-assisted and laparoscopic adrenalectomy for pheochromocytoma : a systematic review and meta-analysis", J Robot Surg, 18, pp.115~ (2024)
70. Ilanchezhian M, "Emerging treatments for advanced", metastatic pheochromocytoma and paraganglioma, 2020, pp.21, 85~
71. "FDA approves AZEDRA specified use in pheochromocytomas", paragangliomas, 2018, pp.59, 17N~
72. Pryma DA, "Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma", J Nucl Med, 60, pp.623~630 (2019)
73. Thorpe MP, "Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG", J Clin Endocrinol Metab, 105, pp.e494~e501 (2020)
74. O’Kane GM, "A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma : the SNIPP trial", Br J Cancer, 120, pp.1113~1119 (2019)
75. Baudin E, "Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial", Lancet, 403, pp.1061~1070 (2024)
76. Plouin PF, "European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma", Eur J Endocrinol, 174, pp.G1~10 (2016)

관련 논문AI추천